Clinical trials: Chronic Disease Management
Pulmonary Disease, Chronic Obstructive
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This multicenter study will be conducted to compare the effect of FF/UMEC/VI with FF/VI plus UMEC on lung function after 24 weeks of treatment.
- Trial name
- NCT02729051
- Testing
- FF/UMEC/VI, FF/VI, UMEC
- Where
- 127 sites in Argentina, Australia and 10 more
- Volunteers
- 1,055 people
- Sponsor
- GlaxoSmithKline
Diabetic Peripheral Neuropathic Pain
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The primary purpose of this study is to evaluate the safety and efficacy of medical cannabis aerosol containing 0.25, 0.50, 1.0 milligrams (mg) delta (Δ) 9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to…
- Trial name
- NCT06490445
- Testing
- Medical Cannabis
- Where
- 38 sites in Australia, Czechia and 3 more
- Volunteers
- 122 people
- Sponsor
- Syqe Medical
Chronic Obstructive Pulmonary Disease (COPD)
Phase IV O2 Consumption Study in COPD Patients.
A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.
- Trial name
- NCT02533505
- Testing
- Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Chronic Liver Disease (CLD)
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
- Trial name
- NCT07521241
- Testing
- AD-230, AD-2301
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Chronic Hepatitis C
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
This study is designed to assess the safety and tolerability of boceprevir dosed 800 mg three times daily (TID) orally (PO) in combination with Peginterferon alfa-2b (PEG2b) 1.5 mcg/kg once a week (QW) administered subcutaneously…
- Trial name
- NCT01641666
- Testing
- Boceprevir, Peginterferon Alfa-2b 1.5 mcg/kg/week, Ribavirin
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
- Trial name
- NCT03897075
- Testing
- Tildrakizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 99 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Chronic Pain
Staff Experiences of Using Virtual Reality in a Pain Management Group
Immersive Virtual Reality is a fast developing technology that allows a number of opportunities to engage people in activities that they otherwise might find difficult.
- Trial name
- NCT04259957
- Testing
- Immersive Virtual Reality
- Where
- United Kingdom
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- InHealth Group
Hepatitis C
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects
- Trial name
- NCT01979939
- Testing
- DCV/ASV/BMS-791325
- Where
- 66 sites in United States, Australia and 3 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB)…
- Trial name
- NCT01023230
- Testing
- DV-601, Entecavir
- Where
- 4 sites in Poland
- Volunteers
- 14 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis C, Chronic
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
The purpose of this study is to assess the efficacy of a 12-week regimen containing simeprevir, daclatasvir and sofosbuvir in participants with decompensated liver disease (the liver function is insufficient) due to genotype 1 or…
- Trial name
- NCT02262728
- Testing
- Simeprevir, Daclatasvir, Sofosbuvir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Obstructive Pulmonary Disease (COPD)
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
- Trial name
- CRESCENDO (NCT05492877)
- Testing
- Mitiperstat (AZD4831)
- Where
- 101 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Urticaria
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)
The purpose of this study was to determine the effect of desloratadine treatment on quality of life, daytime functioning, quality of sleep, symptoms, and disease severity in patients who had hives for 6 weeks or longer.
- Trial name
- NCT00795158
- Testing
- desloratadine
- Volunteers
- 282 people
- Sponsor
- Organon and Co
Anemia
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin.
- Trial name
- NCT00048035
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Mild to Moderate Traumatic Brain Injury
PoNS Clinical Experience Program (TBI)
Brief Summary: Prospective, cohort, open-label study. The cohort consists of people who have a chronic balance dysfunction due to a mild to moderate traumatic brain injury (TBI).
- Trial name
- NCT03732755
- Testing
- PoNS Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Helius Medical Inc
Chronic Fatigue Syndrome
Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)
Chronic fatigue syndrome (CFS) is a devastating and complex disorder. People with CFS experience overwhelming fatigue and a host of other symptoms that are not improved by bed rest.
- Trial name
- NCT01793415
- Testing
- IodoCarb (r)
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- PharmaLundensis AB
Respiratory System Disease, Chronic Obstructive Pulmonary Disease
The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)
The purpose of the study is to prove the clinical superiority of respiratory rehabilitation software "Redpill Breath" and evaluate the clinical improvement effect by 6-minute walk test of the software, compared to the manual…
- Conditions
- Respiratory System Disease, Chronic Obstructive Pulmonary Disease, Asthma Copd, Lung Cancer
- Trial name
- NCT05299385
- Testing
- Conventional rehabilition treatment(e.g leaflet) educated by hospital, Digital treatment based on Respiratory Rehabilitation Software
- Where
- 3 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Lifesemantics Corp.
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Peripheral Neuropathic Pain
- Trial name
- NCT07072468
- Testing
- VMD-3866 Gel
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- VM Therapeutics LLC
Renal Insufficiency Chronic
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally.
- Trial name
- NCT07262333
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Chronic Wounds, Diabetes
FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers
FGF-1 is being used for the treatment of patients with diabetic or venous stasis ulcers. Procedure includes topical administration of FGF-1 or placebo and evaluation of safety, pharmacokinetics, and wound improvement.
- Conditions
- Chronic Wounds, Diabetes, Venous Stasis Ulcers
- Trial name
- NCT00425178
- Testing
- FGF-1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Venturis Therapeutics, Inc.
Viral Hepatitis
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
- Trial name
- NCT06903338
- Testing
- Tobevibart, Elebsiran
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 124 people
- Sponsor
- Vir Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.